Skip to main content
. Author manuscript; available in PMC: 2016 Jul 13.
Published in final edited form as: Cancer Cell. 2015 Jul 2;28(1):70–81. doi: 10.1016/j.ccell.2015.05.010

Figure 3. PF-06463922 ALK target inhibition PK/PD relationships in ALK fusion driven subcutaneous tumor xenograft models in mice.

Figure 3

Mini-pump infusion study in H3122 model expressing endogenous EML4-ALKWT(A), H3122 model expressing engineered EML4-ALKL1196M (B), H3122 model expressing engineered human EML4-ALKG1269(C), 3T3 model expressing engineered human EML4-ALKG1202R (D). Tumor sizes (left) and pALK level and PF-06463922 free plasma concentration (right) of each group are indicated. ALK phosphorylation in tumors was measured at the time of sacrifice following the last tumor volume measurement. The tumors were collected and processed immediately after sacrifice. Tumor volumes, ALK phosphorylation and plasma concentration values are presented as mean +/− SEM (n=8–12). See also Figure S3, Table S2, Table S3 and Table S4.